LDL-apheresis as long-term treatment in severe hyperlipidemia using differing methods.

Area of Science:

• Cardiology
• Metabolic Disorders
• Medical Technology

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol.
• Patients with FH resistant to diet and drugs require advanced treatment options.
• Lipoprotein apheresis is a therapeutic option for severe, refractory hypercholesterolemia.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of low-density lipoprotein (LDL) apheresis in FH patients.
• To compare the effectiveness of different LDL apheresis systems.
• To assess the impact of LDL apheresis on lipid profiles and patient well-being.

Main Methods:

• 34 patients with drug-resistant FH underwent LDL apheresis for an average of 72.8 months.
• Four different apheresis systems were utilized: Liposorber, Therasorb, Lipopak, and Dali.
• Lipid levels (total cholesterol, LDL, HDL, triglycerides, Lp(a)) and adverse events were monitored.

Main Results:

• All methods significantly reduced total cholesterol (51.9%), LDL (49.8%), Lp(a) (69.8%), and triglycerides (58.8%), while increasing HDL (9.8%).
• Severe side effects were rare (0.5%).
• 31 patients reported improved well-being and performance.
• Lipopak (immunoadsorption) showed superior Lp(a) reduction (-57%) compared to other systems.

Conclusions:

• Long-term LDL apheresis is a safe and effective treatment for FH patients resistant to conventional therapies.
• While overall lipid reduction is comparable across systems, immunoadsorption with Lp(a) columns is most effective for reducing high Lp(a) levels.
• LDL apheresis offers significant clinical benefits, including improved patient well-being.